{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-130779","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.973069+00:00","generated_at":"2026-06-02T23:08:38.671639+00:00","sec_items":["1.01","3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Galera Therapeutics adopts limited-duration poison pill after recent stock accumulations","bullets":["Board adopted Rights Agreement effective May 2, 2024, responding to recent accumulations of common stock.","Each outstanding common share receives one right; triggers at 10% beneficial ownership without Board approval.","Upon trigger, rights holders (except acquirer) can buy shares at 50% discount; rights expire May 2, 2025.","Record date for dividend of rights is May 20, 2024; exercise price $1.50 per right."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-130779","json":"https://secwatch.observer/filing/0001193125-24-130779.json","markdown":"https://secwatch.observer/filing/0001193125-24-130779.md","text":"https://secwatch.observer/filing/0001193125-24-130779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524130779/0001193125-24-130779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524130779/d835891d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:08:38.671639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a19383ed0e3620229f0222a302e0e0a440e55b8","claim":"Galera Therapeutics, Inc.: Board approved a Certificate of Designation creating Series A Junior Participating Preferred Stock in connection with the adoption of a stockholder rights agreement (effective 2024-05-03).","evidence_excerpt":"In connection with the adoption of the Rights Agreement described in Item 3.03 of this Current Report, the Board approved a Certificate of Designation of Series A Junior Participating Preferred Stock, which designates the rights, preferences and privileges of 200,000 shares of a series of the Company’s preferred stock, par value $0.001 per share, designated as Series A Junior Participating Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524130779/0001193125-24-130779-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-05-03"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}